Views & Analysis Health Innovators: Eliot Forster, F-Star In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star
News Merck KGaA takes second option from cancer immunotherapy pac... Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics.
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
Views & Analysis Will the UK ever produce a world-class biotech company? Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
